SCRI Development InnovationsLLC
everolimus(SCRI Development Innovations, LLC)은 Renal Cell Carcinoma 표적 ADC로, Intracranial Meningioma 영역에서 개발·상용화 중입니다. 작용기전: targeting RCC-associated minor histocompatibility antigen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT00869999). PK: t½ 30 h. 차별점: novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib.
Renal Cell Carcinoma
Intracranial Meningioma
Discontinued
lipid nanoparticle therapy with mTOR inhibition promotes regulatory T cells and limits allergy
novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib
targeting RCC-associated minor histocompatibility antigen
T-cell responses, eosinophil activation, airway hyperresponsiveness, mucus production, and markers of cytotoxicity
apoptosis and mitogen-activated protein kinase (MAPK) signaling pathways
biomarker for treatment efficacy
resistance to monotherapies such as everolimus
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
SCRI Development InnovationsLLC
everolimus(SCRI Development Innovations, LLC)은 Renal Cell Carcinoma 표적 ADC로, Intracranial Meningioma 영역에서 개발·상용화 중입니다. 작용기전: targeting RCC-associated minor histocompatibility antigen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 38% (ClinicalTrials.gov NCT00869999). PK: t½ 30 h. 차별점: novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib.
Renal Cell Carcinoma
Intracranial Meningioma
Discontinued
lipid nanoparticle therapy with mTOR inhibition promotes regulatory T cells and limits allergy
novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib
targeting RCC-associated minor histocompatibility antigen
T-cell responses, eosinophil activation, airway hyperresponsiveness, mucus production, and markers of cytotoxicity
apoptosis and mitogen-activated protein kinase (MAPK) signaling pathways
biomarker for treatment efficacy
resistance to monotherapies such as everolimus
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.